200 related articles for article (PubMed ID: 30410066)
1. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.
Atrash S; Robinson M; Slaughter D; Aneralla A; Brown T; Robinson J; Ndiaye A; Sprouse C; Zhang Q; Symanowski JT; Friend R; Voorhees PM; Usmani SZ; Bhutani M
Blood Cancer J; 2018 Nov; 8(11):107. PubMed ID: 30410066
[No Abstract] [Full Text] [Related]
2. The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor.
Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Bladé J; Rosiñol L
Leukemia; 2018 Sep; 32(9):2082-2094. PubMed ID: 29795240
[No Abstract] [Full Text] [Related]
3. Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'.
Lakshman A; Ravi P; Rajkumar SV; Kumar SK
Leukemia; 2018 Sep; 32(9):2083-2085. PubMed ID: 29802327
[No Abstract] [Full Text] [Related]
4. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
Wu V; Moshier E; Leng S; Barlogie B; Cho HJ; Jagannath S; Madduri D; Mazumdar M; Parekh S; Chari A
Blood Adv; 2018 Jun; 2(12):1470-1479. PubMed ID: 29945937
[TBL] [Abstract][Full Text] [Related]
5. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
[TBL] [Abstract][Full Text] [Related]
6. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.
Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Magnano L; Tovar N; Rodríguez-Lobato LG; Calvo X; Aróstegui JI; Díaz T; Lozano E; Rozman M; Yagüe J; Bladé J; Rosiñol L
Leukemia; 2018 Jun; 32(6):1427-1434. PubMed ID: 29463830
[TBL] [Abstract][Full Text] [Related]
7. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
[TBL] [Abstract][Full Text] [Related]
8. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
Gran C; Luong V; Bruchfeld JB; Liwing J; Afram G; Lund J; Usmani S; Alici E; Nahi H
Am J Hematol; 2021 Mar; 96(3):E63-E65. PubMed ID: 33264449
[No Abstract] [Full Text] [Related]
9. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A
Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, incidence and survival of smoldering multiple myeloma in the United States.
Ravindran A; Bartley AC; Holton SJ; Gonsalves WI; Kapoor P; Siddiqui MA; Hashmi SK; Marshall AL; Ashrani AA; Dispenzieri A; Kyle RA; Rajkumar SV; Go RS
Blood Cancer J; 2016 Oct; 6(10):e486. PubMed ID: 27768092
[No Abstract] [Full Text] [Related]
11. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Correa JG; Cibeira MT; Tovar N; Isola I; Pedrosa F; Díaz T; Lozano E; Magnano L; Rosiñol L; Bladé J; Fernández de Larrea C
Br J Haematol; 2017 Dec; 179(5):849-851. PubMed ID: 27605200
[No Abstract] [Full Text] [Related]
12. Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.
Muchtar E; Kumar SK; Magen H; Gertz MA
Leuk Lymphoma; 2018 Feb; 59(2):288-299. PubMed ID: 28592156
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models.
Hill E; Dew A; Morrison C; Yuan C; Stetler-Stevenson M; Landgren O; Kazandjian D
JAMA Oncol; 2021 Jan; 7(1):132-134. PubMed ID: 33211080
[TBL] [Abstract][Full Text] [Related]
14. Timing of treatment of smoldering myeloma: early treatment.
Mateos MV; González-Calle V
Blood Adv; 2018 Nov; 2(21):3045-3049. PubMed ID: 30425068
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.
Bustoros M; Kastritis E; Sklavenitis-Pistofidis R; Liu CJ; Hornburg K; Kanellias N; Kim G; Liu D; Gavriatopoulou M; Marinac CR; Roussou M; Migkou M; Noonan K; Reyes K; Rivotto B; Neuse CJ; Ziogas DC; Laubach J; Terpos E; Anderson KC; Richardson PG; Ghobrial IM; Dimopoulos MA
Am J Hematol; 2019 May; 94(5):E146-E149. PubMed ID: 30773670
[No Abstract] [Full Text] [Related]
16. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.
Ravi P; Kumar S; Larsen JT; Gonsalves W; Buadi F; Lacy MQ; Go R; Dispenzieri A; Kapoor P; Lust JA; Dingli D; Lin Y; Russell SJ; Leung N; Gertz MA; Kyle RA; Bergsagel PL; Rajkumar SV
Blood Cancer J; 2016 Jul; 6(7):e454. PubMed ID: 27471870
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.
Dalla Palma B; Marchica V; Pedrazzoni M; Accardi F; Notarfranchi L; Goldoni M; De Luca F; Costa F; Storti P; Toscani D; Sammarelli G; Bonomini S; Aversa F; Giuliani N
Br J Haematol; 2018 Dec; 183(5):812-815. PubMed ID: 29143308
[No Abstract] [Full Text] [Related]
18. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Willrich MAV; Murray DL; Kyle RA
Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
[TBL] [Abstract][Full Text] [Related]
19. Timing treatment for smoldering myeloma: is earlier better?
Hernández JÁ; Martínez-López J; Lahuerta JJ
Expert Rev Hematol; 2019 May; 12(5):345-354. PubMed ID: 30907176
[TBL] [Abstract][Full Text] [Related]
20. Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis.
Visram A; Rajkumar SV; Kapoor P; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Gonsalves W; Warsame R; Muchtar E; Leung N; Baughn LB; Kyle RA; Kumar S
Blood Cancer J; 2021 Nov; 11(11):186. PubMed ID: 34836942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
